Skip to content
Narrow screen resolution Wide screen resolution Increase font size Decrease font size Default font size
Home Page arrow Products arrow Joint Ventures
Joint Ventures with the Industry / Privately Funded Research PDF Print E-mail

Molecular imaging & targeted therapy with radiopeptides

fs In 2007, a 5-year Collaboration Agreement was established between the Molecular Radiopharmacy team, I/R-RP, NCSR “Demokritos”, Erasmus MC, University of Rotterdam, The Netherlands and Biosynthema, Inc., St. Louis, USA, with the aim to promote research on diagnostic – therapeutic radiopeptides for oncological applications and to clinically test candidates for eventual commercial exploitation. The Project “Molecular Imaging & Targeted Therapy with Radiopeptides” is currently focused on the diagnosis and therapy of neuroendocrine tumors, but also prostate and breast cancer. Molecular Radiopharmacy Researchers involved in this project: Berthold A. Nock and Theodosia Maina. Budget 250 k€

[99mTc]Demogastrin 2 – 99mTc-labeled bombesin-like antagonists

In 2007 a long-existing cooperation between the Molecular Radiopharmacy team, I/R-RP, NCSR “Demokritos”, and Biomedica Life Sciences, SA, continues successfully to work on the design, evaluation and commercial exploitation of 99mTc-based diagnostic radiopeptides with oncological application. The cooperation is currently focused on the development of 99mTc-labeled bombesin-like antagonists for prostate cancer imaging with the significant contribution of the Institute of Pathology, University of Bern, Bern, Switzerland. Furthermore, the commercialization of [99mTc]Demogastrin 2 is actively pursued. This diagnostic radiopharmaceutical, essentially developed by the Molecular Radiopharmacy team of NCSR “Demokritos”, has already acquired the “orphan drug” status by EMEA for the diagnosis of human medullary thyroid cancer (MTC). [99mTc]Demogastrin 2 is currently undergoing Phase I clinical trials in Erasmus MC, University of Rotterdam, The Netherlands. A GMP-kit formulation is under development to acquire clearance for Phase II multi-center clinical trials aiming toward eventual registration of the product by EMEA. Molecular Radiopharmacy Researchers involved in this project: Berthold A. Nock and Theodosia Maina.

Product Commercialisation

In 2007 the Institute co-founded, along with Biomedica Life Sciences SA, the company BioRP, Hellenic Radiopharmaceuticals S.A. in order to exploit its National and European Licences on Radiopharmaceutical Products. During 2007 all the regulatory-affairs work has been completed along with pilot productions and in 2008 two new radiopharmaceutical compounds MIBI/Demomed® and DMSM/Demomed™ will be produced and distributed in the Greek and International markets. Production is carried out in collaboration with ROTOP Pharmaka A.G., Rosendorf, Germany. BioRP will also co-develop some of the Institute’s innovative radiopharmaceutical compounds and in 2009 will initiate production of specific therapeutic radionuclides such as Yttrium-90 and Lutetium-177. Researchers involved in the project: P. Kyprianidou, I. Pirmettis, M. Papadopoulos, G. Nounesis and G. Pantelias.